指南与共识新发突发、热带与寄生虫病

美国感染病学会新冠肺炎诊断指南:抗原检测(2023年1月)

The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023).
指南 / 共识 · Clin Infect Dis · 2024-01-01

美国感染病学会(IDSA)组织多学科专家组系统综述截至2022年4月1日的文献,采用GRADE方法制定10条关于SARS-CoV-2抗原检测的诊断推荐,覆盖有症状和无症状人群及单次与重复检测策略。

要点

  • FDA紧急使用授权的SARS-CoV-2抗原检测相比核酸扩增检测敏感性低至中等、特异性高。
  • 抗原检测敏感性取决于有无症状,有症状者还取决于症状出现后的检测时机。
  • 多数情况下阳性抗原结果无需确认即可据此处理。

核心结论

  • 快速RT-PCR或实验室核酸扩增检测仍是诊断SARS-CoV-2感染的首选方法。
  • 当及时分子检测不可及或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离的效用给出推荐。

研究设计与样本

  • IDSA召集多学科专家组(感染病临床医生、临床微生物学家和系统文献综述专家)识别并优先排序临床问题。
  • 对截至2022年4月1日的同行评议已发表文献进行综述。
  • 采用GRADE方法评估证据确定性并制定检测推荐。
  • 共制定10条诊断推荐,涉及有症状和无症状个体的抗原检测及单次与重复检测策略。

主要发现

  • FDA紧急使用授权的SARS-CoV-2抗原检测相比核酸扩增检测具有高特异性和低至中等敏感性。
  • 抗原检测敏感性取决于有无症状,有症状患者中还取决于症状出现后的检测时机。
  • 多数情况下阳性抗原结果无需确认即可据此处理。
  • 即时检测结果与实验室检测结果可比,观察下或未观察下自采样检测结果相似。
  • 建模提示重复抗原检测较单次检测提高敏感性,但无实证数据回答该问题。

关键数值与推荐

  • 支持抗原检测使用的现有证据总体质量被评为极低至中等。
  • 快速RT-PCR或实验室核酸扩增检测仍是诊断SARS-CoV-2感染的首选检测方法。
  • 当及时分子检测不可及或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离的效用给出推荐。

临床怎么用

  • FDA紧急使用授权的SARS-CoV-2抗原检测可用于诊断COVID-19。
  • 多数情况下阳性抗原结果无需确认即可据此处理。
  • 当及时分子检测不可及或后勤上不可行时,抗原检测有助于识别SARS-CoV-2感染者。
  • 快速RT-PCR或实验室核酸扩增检测仍是诊断SARS-CoV-2感染的首选方法。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离的效用给出推荐。

局限性

  • 建模提示重复抗原检测较单次检测提高敏感性,但无实证数据回答该问题。
  • 数据不足以就抗原检测指导COVID-19患者解除隔离的效用给出推荐。
  • 支持抗原检测使用的现有证据总体质量被评为极低至中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoassays designed to detect SARS-CoV-2 protein antigens (Ag) are commonly used to diagnose COVID-19. The most widely used tests are lateral flow assays that generate results in approximately 15 minutes for diagnosis at the point-of-care. Higher throughput, laboratory-based SARS-CoV-2 Ag assays have also been developed. The number of commercially available SARS-CoV-2 Ag detection tests has increased rapidly, as has the COVID-19 diagnostic literature. The Infectious Diseases Society of America (IDSA) convened an expert panel to perform a systematic review of the literature and develop best-practice guidance related to SARS-CoV-2 Ag testing. This guideline is an update to the third in a series of frequently updated COVID-19 diagnostic guidelines developed by the IDSA. IDSA's goal was to develop evidence-based recommendations or suggestions that assist clinicians, clinical laboratories, patients, public health authorities, administrators, and policymakers in decisions related to the optimal use of SARS-CoV-2 Ag tests in both medical and nonmedical settings. A multidisciplinary panel of infectious diseases clinicians, clinical microbiologists, and experts in systematic literature review identified and prioritized clinical questions related to the use of SARS-CoV-2 Ag tests. A review of relevant, peer-reviewed published literature was conducted through 1 April 2022. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and make testing recommendations. The panel made 10 diagnostic recommendations that address Ag testing in symptomatic and asymptomatic individuals and assess single versus repeat testing strategies. US Food and Drug Administration (FDA) SARS-CoV-2 Ag tests with Emergency Use Authorization (EUA) have high specificity and low to moderate sensitivity compared with nucleic acid amplification testing (NAAT). Ag test sensitivity is dependent on the presence or absence of symptoms and, in symptomatic patients, on timing of testing after symptom onset. In most cases, positive Ag results can be acted upon without confirmation. Results of point-of-care testing are comparable to those of laboratory-based testing, and observed or unobserved self-collection of specimens for testing yields similar results. Modeling suggests that repeat Ag testing increases sensitivity compared with testing once, but no empirical data were available to inform this question. Based on these observations, rapid RT-PCR or laboratory-based NAAT remain the testing methods of choice for diagnosing SARS-CoV-2 infection. However, when timely molecular testing is not readily available or is logistically infeasible, Ag testing helps identify individuals with SARS-CoV-2 infection. Data were insufficient to make a recommendation about the utility of Ag testing to guide release of patients with COVID-19 from isolation. The overall quality of available evidence supporting use of Ag testing was graded as very low to moderate.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hayden MK, Hanson KE, Englund JA, et al. The Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Antigen Testing (January 2023). Clin Infect Dis. 2024. PMID: 36702617. doi:10.1093/cid/ciad032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。